| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥7240.7B | ¥7180.4B | +0.8% |
| Operating Income | ¥332.1B | ¥310.0B | +7.1% |
| Ordinary Income | ¥336.0B | ¥307.0B | +9.4% |
| Net Income | ¥255.2B | ¥222.9B | +15.0% |
| ROE | 6.1% | 5.5% | - |
FY2025 Q3 cumulative results showed revenue of 724.1B yen (YoY +0.8%) with operating income of 33.2B yen (+7.1%), ordinary income of 33.6B yen (+9.4%), and net income of 25.5B yen (+14.5%). While revenue remained essentially flat year-over-year, the company achieved profit growth through improved operational efficiency and gross profit margin expansion of 0.9 percentage points. Operating margin stood at 4.6%, reflecting the company's ROIC-focused management approach. Special items included business exit losses of approximately 2.6B yen in China and gains from negative goodwill of 1.7B yen from M&A activities, along with investment securities sales gains of 2.8B yen. The company maintained its full-year guidance of 964.0B yen in revenue and 40.7B yen in operating income, indicating performance is tracking within expected parameters.
Revenue growth of +0.8% reflects mixed segment performance, with Electronics and Energy (+15.9% in gross profit) and Life and Healthcare (+9.4% in gross profit) offsetting declines in Mobility (-7.6% in gross profit) and Functional Materials (-3.6% in gross profit). The automotive-related business faced headwinds from reduced production volumes at certain EV customers, while semiconductor materials and food ingredients showed strength. Operating income growth of +7.1% exceeded revenue growth, driven by gross profit margin improvement of 0.9 points through portfolio optimization and business mix enhancement under ROIC management principles.
The gap between ordinary income (+9.4%) and operating income (+7.1%) was modest, reflecting stable non-operating results. The variance between ordinary income of 33.6B yen and net income of 25.5B yen includes special items: business exit losses of approximately 2.6B yen from withdrawing from glass substrate processing operations in China, negative goodwill gains of 1.7B yen from M&A transactions, and investment securities sales gains of 2.8B yen. These non-recurring factors contributed approximately 0.9B yen net gain to special income, making the underlying operating performance the primary driver of profit growth.
This represents a revenue stable/profit up pattern, where operational improvements and business portfolio optimization drove profitability expansion despite limited top-line growth.
Electronics and Energy (core business by operating profit scale) delivered the strongest performance with sales of 130.8B yen and operating income of 11.3B yen (+28.0% YoY). This segment is the largest profit contributor and was the primary driver of consolidated profit growth. Sales of semiconductor materials increased, with Nagase ChemteX's modified epoxy resins for AI server semiconductors performing solidly despite US-China trade uncertainties. The Pac Tech Group also contributed strong results. Operating margin in this segment is approximately 8.7%, significantly above the consolidated average.
Life and Healthcare recorded sales of 228.8B yen with operating income of 7.0B yen (+124.1% YoY in gross profit terms). The substantial profit improvement came from increased sales of intermediates and pharmaceutical raw materials, improved profitability at Nagase Viita in cosmetic ingredients, and volume growth at the Prinova Group in food ingredients. This segment drove the second-largest contribution to profit growth.
Functional Materials posted sales of 115.9B yen with operating income of 6.8B yen (-9.5% YoY in gross profit terms). Paint raw materials for automotive and construction applications declined due to reduced demand, though semiconductor material sales increased. Advanced Materials and Processing showed sales of 154.9B yen with operating income of 5.5B yen (+0.5% YoY in gross profit terms), benefiting from improved product mix despite lower resin sales for office equipment.
Mobility recorded sales of 98.8B yen with operating income of 2.7B yen (-21.7% YoY in gross profit terms), representing the weakest performance. Resin sales were flat while functional materials and components for interior/exterior and electrification applications declined, reflecting automotive industry headwinds. Operating margin in this segment is approximately 2.8%, indicating profitability challenges.
Profitability: ROE 6.0% (prior year not disclosed but showing improvement), Operating Margin 4.6%, Net Profit Margin 3.5%, Gross Profit Margin 19.2%. The company is pursuing ROIC management with gross profit margin improving 0.9 points year-over-year.
Cash Quality: OCF/Net Income 1.15x (29.3B yen operating CF / 25.5B yen net income), indicating cash-backed earnings. However, FCF was negative 13.9B yen due to substantial investing activities.
Investment: CapEx/Depreciation 1.80x (21.8B yen capex / 12.1B yen D&A), reflecting aggressive growth investment stance aligned with the company's strategy to invest approximately 80B yen in focus areas (food, semiconductors, life sciences).
Financial Health: Equity Ratio 48.4% (prior 50.3%), Current Ratio 183.4%, Quick Ratio 134.3%. Interest-bearing debt totaled 72.9B yen with Debt/EBITDA of 1.61x and interest coverage of 13.34x, indicating conservative leverage levels.
Operating CF: 29.3B yen (1.15x Net Income), demonstrating adequate cash generation from core operations. The OCF/Net Income ratio above 1.0x indicates earnings quality is supported by cash flow, though the OCF/EBITDA ratio of 0.65x suggests room for improvement in cash conversion efficiency.
Investing CF: -43.2B yen, primarily driven by multiple M&A transactions including the acquisition of SACHEM's Asia business (101M USD), Aplinova in Brazil, and establishment of Nagase Diagnostics. Capital expenditures of 21.8B yen support expansion in focus areas. Property, plant and equipment increased 28.3% from prior year, reflecting the company's active investment strategy.
Financing CF: Significant cash outflows included treasury stock purchases of 18.4B yen as part of the 100% total return commitment. Short-term borrowings decreased 46.8% from 42.3B yen to 22.5B yen, indicating debt reduction alongside cash utilization. Dividends were paid in line with the annual 55 yen per share guidance.
FCF: -13.9B yen (Operating CF 29.3B yen - CapEx 21.8B yen - M&A related investments 21.4B yen), negative due to aggressive growth investments. Cash position decreased 34.4% to 43.5B yen.
Cash generation: Needs Monitoring. While operating cash flow generation is adequate, the combination of substantial M&A activity, elevated capex, and shareholder returns (dividends plus buybacks) resulted in significant cash drawdown. The sustainability of this investment and return pace depends on improving working capital efficiency and generating returns from deployed capital.
Ordinary vs Net Income: The gap between ordinary income of 33.6B yen and net income of 25.5B yen (before tax profit of 35.3B yen) reflects special items totaling approximately 0.9B yen net gain. Key non-recurring items include: business exit losses of approximately 2.6B yen from withdrawing from glass substrate processing operations in China, negative goodwill of approximately 1.7B yen from M&A transactions, and investment securities sales gains of 2.8B yen. After adjusting for these items, recurring net income would be approximately 24.6B yen, suggesting underlying earnings quality is sound.
Non-operating income composition is not material relative to operating income, with the ordinary income exceeding operating income by only 1.2%, indicating minimal reliance on financial income or equity method gains.
Accruals and cash backing: OCF of 29.3B yen covers net income of 25.5B yen at 1.15x, indicating positive earnings quality. However, working capital metrics show deterioration: days sales outstanding increased to 168 days, days inventory outstanding to 106 days, and cash conversion cycle extended to 171 days. This working capital expansion represents a cash drag and indicates that receivables and inventory management require attention. The OCF/EBITDA ratio of 0.65x confirms that while earnings convert to cash, the conversion efficiency has declined and represents a quality concern requiring improvement in working capital management.
Full-year guidance maintained at revenue 964.0B yen (+2.0% YoY), operating income 40.7B yen (+4.1% YoY), and ordinary income 40.6B yen (+5.8% YoY).
Progress rate versus full-year guidance: Q3 cumulative results show revenue at 75.1% of full-year target, operating income at 81.6%, and ordinary income at 82.8%. With Q3 representing 75% of the fiscal year, operating and ordinary income are tracking 6-8 points ahead of the standard 75% benchmark, indicating solid progress. Net income of 25.5B yen represents 81.0% of the full-year target of 31.5B yen, also ahead of pace.
Management commentary indicates performance is tracking within expected parameters across business segments, with positive and negative factors offsetting. Specifically, Nagase ChemteX's modified epoxy resins for mobile devices are weaker than expected while AI server semiconductor applications remain solid despite US-China uncertainty. The Prinova Group's Solutions business is performing better than expected. Given these offsetting factors, management chose not to revise guidance.
The ahead-of-pace progress in profits suggests a conservative buffer in the guidance, though Q4 traditionally carries execution risks. No specific quarterly breakdown was provided, but the company appears positioned to meet or potentially exceed full-year targets if current momentum continues.
Dividend policy: Annual dividend of 55 yen per share maintained (Q2 interim: 45 yen, year-end: 45 yen planned, with a 10 yen commemorative dividend included in Q2). Based on full-year net income guidance of 31.5B yen and approximately 105 million shares outstanding, the payout ratio for dividends alone is approximately 18.3%, indicating substantial room for sustainability from an earnings perspective.
Share buybacks: The company repurchased 18.4B yen of treasury stock during the nine-month period as part of its commitment to a 100% total return ratio for two years (FY2024-2025). Combined with dividends of approximately 5.8B yen, total shareholder returns reached approximately 24.2B yen.
Total return ratio: With net income of 25.5B yen and total returns of 24.2B yen, the total return ratio reaches approximately 95%, approaching the company's 100% target. This aggressive return policy is funded partially through FCF (which was negative) and partially through balance sheet capacity and debt utilization.
Sustainability assessment: Dividend payments alone are highly sustainable with a modest payout ratio of 18.3% and adequate cash reserves of 43.5B yen covering short-term debt of 22.5B yen by 1.93x. However, the 100% total return commitment including buybacks exceeds current FCF generation and relies on balance sheet flexibility. Management has stated this 100% policy is limited to two years, suggesting awareness of the sustainability constraint. Post-FY2025, shareholder returns will likely moderate to align with cash generation capacity unless operational improvements significantly enhance FCF. The combination of equity ratio above 48% and conservative leverage provides near-term capacity to maintain current return levels.
Near-term: (1) Performance trajectory of Nagase ChemteX's modified epoxy resins for AI server semiconductors amid US-China trade dynamics, which could materially impact Electronics and Energy segment results in Q4 and beyond. (2) Recovery pace in automotive-related businesses (Mobility segment) as EV production volumes stabilize among key customers. (3) Integration progress and initial contribution from recent M&A transactions (SACHEM Asia business, Aplinova, Nagase Diagnostics), which collectively target approximately 10B yen in gross profit contribution by FY2030.
Long-term: (1) Achievement of growth investment targets in three focus areas (food, semiconductors, life sciences) with approximately 80B yen in potential investment capacity, targeting cumulative gross profit of approximately 10B yen by FY2030. (2) Realization of ROIC management benefits through improved business portfolio mix and elimination of unprofitable operations, with management targeting reduction of loss-making operations from 2.5B yen in H1 to near zero. (3) Transition of shareholder return policy post-FY2025 following completion of the two-year 100% total return commitment, which will clarify sustainable capital allocation framework. (4) Working capital efficiency improvements, particularly in receivables and inventory management, to enhance cash conversion and support self-funded growth investments.
Industry Position (Reference - Proprietary Analysis)
Profitability: ROE 6.0% substantially exceeds the trading industry median of 3.7% (Q3 2025, n=15), positioning the company in the upper tier of industry peers. Operating Margin 4.6% aligns with the industry median of 3.2% (IQR: 1.3%-4.6%), indicating mid-to-upper tier operational efficiency. Net Profit Margin 3.5% exceeds the industry median of 2.0% (IQR: 1.0%-3.9%), demonstrating above-average profitability.
Financial Health: Equity Ratio 48.4% is near the industry median of 47.8% (IQR: 43.0%-55.5%), indicating a balanced capital structure consistent with sector norms. Current Ratio 183.4% falls below the industry median of 188% (IQR: 164%-238%), though still within the healthy range for short-term liquidity.
Efficiency: Asset Turnover 0.84x significantly underperforms the industry median of 1.06x (IQR: 0.70-1.32), suggesting below-average asset utilization efficiency. This lower turnover reflects the company's asset-intensive manufacturing operations and recent acquisition-driven asset base expansion. Operating Working Capital Turnover of 171 days substantially exceeds the industry median of 54 days, driven by extended receivables (168 days vs. industry median 74 days) and inventory (106 days vs. industry median 51 days), representing a clear efficiency gap requiring management attention.
Growth: Revenue Growth of 0.8% YoY falls below the industry median of 2.6% (IQR: -5.3% to +10.8%), positioning the company in the lower half of peers for top-line expansion.
Capital Efficiency: Return on Invested Capital positioning could not be precisely benchmarked due to calculation methodology differences, but the company's ROIC management focus suggests awareness of the need to improve returns on deployed capital.
Industry: Trading sector (n=15 companies), Comparison: Q3 2025 fiscal period, Source: Proprietary analysis. The company demonstrates above-average profitability metrics but faces efficiency challenges in asset utilization and working capital management relative to industry peers.
Working Capital Efficiency Deterioration: Days sales outstanding of 168 days (vs. industry median 74 days), days inventory outstanding of 106 days (vs. industry median 51 days), and cash conversion cycle of 171 days (vs. industry median 54 days) represent substantial efficiency gaps versus industry peers. This working capital expansion consumed cash and reduced OCF/EBITDA to 0.65x, constraining the company's ability to self-fund growth investments and shareholder returns. Failure to improve working capital management could necessitate increased borrowing or moderation of investment and return policies. Quantifiable impact: each 10-day improvement in CCC would release approximately 2B yen in cash based on current revenue run rate.
Return on Deployed Capital Execution Risk: The company invested over 43B yen in M&A and capex during the nine-month period (Property, plant and equipment +28.3%), targeting approximately 10B yen in incremental gross profit by FY2030 from recent acquisitions. This implies a 4-5 year payback period requiring successful integration and market execution. Key risks include: SACHEM Asia business achieving targeted synergies in high-purity chemicals amid semiconductor market volatility, Aplinova delivering expected returns in Brazilian food ingredients market, and Nagase Diagnostics successfully expanding diagnostic enzyme business internationally. If these investments underperform, the company's ROIC improvement targets and investment thesis would be undermined. With equity ratio at 48.4% and increased leverage to fund these investments, balance sheet flexibility for future M&A would be constrained if returns disappoint.
US-China Trade and Semiconductor Market Exposure: Nagase ChemteX's modified epoxy resins for AI server semiconductors represent a material profit contributor in the Electronics and Energy segment (the largest profit segment at 11.3B yen operating income). Management noted explicit uncertainty regarding market outlook due to US-China relations. Simultaneously, mobile device semiconductor applications are performing below expectations. Given this segment's 28.0% YoY profit growth drove consolidated performance, any material deterioration in semiconductor materials demand or pricing would significantly impact consolidated results. The concentration of profit growth in this geopolitically sensitive segment creates earnings volatility risk. Additionally, the recent business exit in China (glass substrate processing with 2.6B yen loss) demonstrates ongoing China exposure management challenges.
Margin Expansion Through Portfolio Optimization: The company achieved operating profit growth of 7.1% while revenue grew only 0.8%, with gross profit margin improving 0.9 points to 19.2%. This operating leverage demonstrates tangible progress in ROIC-focused management through business mix improvement and elimination of unprofitable operations (management reduced loss-making operations from approximately 2.5B yen to 1.0B yen in H1). The Electronics and Energy segment, which carries an approximately 8.7% operating margin versus the consolidated 4.6%, is driving profit mix enhancement. Management's stated goal of reducing losses to near zero and the track record of margin improvement suggest continued operational upside potential independent of revenue growth acceleration. The combination of above-industry profitability metrics (ROE 6.0% vs. industry median 3.7%, net margin 3.5% vs. median 2.0%) with ongoing portfolio refinement indicates sustainable profit quality improvement.
Growth Investment Cycle with Near-Term Cash Consumption: The company is executing an aggressive investment strategy with 80B yen in planned capital deployment across food, semiconductors, and life sciences, reflected in 28.3% growth in property, plant and equipment and over 43B yen deployed in nine months. Management is funding this through a combination of operating cash flow (29.3B yen), debt utilization (though Debt/EBITDA remains conservative at 1.61x), and balance sheet optimization. The two-year 100% total return commitment running through FY2025 compounds near-term cash consumption, resulting in negative FCF of 13.9B yen and 34.4% reduction in cash holdings. This represents a transitional period where the company is prioritizing strategic positioning over near-term cash accumulation. The investment thesis depends on capital deployment discipline and execution of identified return targets (10B yen gross profit contribution by FY2030), with visibility to improve as integration progresses. Post-FY2025, shareholder returns will likely moderate to sustainable levels, potentially improving cash flow stability.
Working Capital Management Critical for Full Potential Realization: The company's OCF/EBITDA ratio of 0.65x and cash conversion cycle of 171 days (versus industry median 54 days) represent the most significant operational efficiency gap. Days sales outstanding of 168 days (vs. industry median 74 days) and days inventory outstanding of 106 days (vs. industry median 51 days) indicate substantial opportunity for improvement. Given the company's scale, each 10-day reduction in CCC would release approximately 2B yen in cash. Improvement to industry median levels would release over 20B yen, materially enhancing self-funded growth capacity and reducing reliance on external financing for the investment program. Management has not explicitly highlighted working capital improvement as a priority initiative, which represents either an unaddressed opportunity or suggests structural factors (e.g., business model characteristics, customer payment terms) that constrain optimization. Working capital efficiency will be a key determinant of whether the company can sustain both growth investments and shareholder returns beyond the current two-year commitment period without increasing leverage beyond conservative levels.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI analysis of PDF earnings presentation
For Nagase & Co., Ltd.’s cumulative results for the first nine months of FY2025, net sales and profits at all levels reached record highs, and the pursuit of ROIC-driven management improved the gross profit margin by 0.9 percentage points. While automotive-related businesses in Functional Materials and Mobility were sluggish, the Prinova Group’s trading business performed well on the back of higher sales volumes, and manufacturing trended toward recovery, centered on the Solutions business. Sales of modified epoxy resins for AI server semiconductors at Nagase ChemteX Corporation were steady despite the impact of U.S.-China relations. Special gains and losses included a loss on withdrawal from operations in China, a bargain purchase gain related to M&A, and a gain on sale of investment securities. The full-year outlook remains unchanged, as performance by business varies but is generally tracking within the expected range.
In the first nine months, net sales and profits at all levels hit record highs; gross profit margin improved by 0.9 percentage points. Prinova Group’s trading business was strong; manufacturing is on a recovery track centered on the Solutions business. Nagase ChemteX’s modified epoxy resins for AI server semiconductors remained steady despite the impact of U.S.-China relations. Recorded special items including a loss on withdrawal from the glass substrate thinning business in China (approximately 2.6 billion yen) and a bargain purchase gain (approximately 1.7 billion yen). Full-year guidance maintained within the expected range, with strengths and weaknesses across businesses offsetting each other.
For the full year, the Company expects net sales of 964.0 billion yen and operating profit of 40.7 billion yen, and performance is generally progressing within the anticipated range. Sales of modified epoxy resins at Nagase ChemteX for AI server semiconductors face market uncertainty due to U.S.-China relations, while sales for mobile devices are weaker than expected. The Prinova Group’s Solutions business is performing better than anticipated. Offsetting strengths and weaknesses across businesses, the outlook remains unchanged.
Management has stated a policy of instilling ROIC-driven management in the final year of the medium-term management plan to improve profitability and efficiency. Shareholder returns will maintain a total payout ratio of 100% for a limited two-year period, while leveraging debt for growth investments. In areas for improvement, the Company will continue to reduce unprofitable businesses and transactions and gradually reduce cross-shareholdings. Capital investment and shareholder returns will be pursued in parallel to enhance corporate value.
Assuming potential investments of approximately 80.0 billion yen in prioritized manufacturing functions (Food, Semiconductors, Life Sciences), actively executing M&A and capital expenditures. Acquired SACHEM’s Asia business for 101M$, expanding the high-purity chemicals business globally, targeting approximately 4.0 billion yen in gross profit in FY2030. Acquired Brazil’s Aplinova to expand the Food business, broadening customer channel foundations in the Global South and targeting approximately 2.0 billion yen in gross profit in FY2030. Established Nagase Diagnostics Co., Ltd. (inheriting the diagnostic enzymes business, etc. from Asahi Kasei Pharma Corporation), targeting approximately 4.0 billion yen in gross profit around FY2030 through overseas expansion. Driving loss reduction in improvement areas, compressing a loss of approximately 2.5 billion yen to below approximately 1.0 billion yen in Q2 FY2025, aiming for zero losses.
Uncertainty in sales of modified epoxy resins for AI server semiconductors at Nagase ChemteX due to the impact of U.S.-China relations. Automotive-related business remains sluggish due to reduced production volumes at certain EV-related customers. Recording a loss of approximately 2.6 billion yen associated with withdrawal from the glass substrate thinning business in China. Efficiency improvements are underway in the Prinova Group’s Nutrition business, with an allowance for doubtful accounts (approximately 1.3 billion yen) recorded in the past. Increase in retirement benefit expenses due to amortization of actuarial differences (approximately 0.3 billion yen negative impact for the full year FY2025).